A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled,Multi-center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots) and will test the hypothesis that omalizumab may reduce the rate of systemic reactions to immunotherapy in patients with persistent allergic asthma.

本研究旨在探讨奥马珠单抗（omalizumab）作为预处理方案，应用于拟接受变应原免疫治疗（allergen immunotherapy，即过敏原注射疗法）的持续性过敏性哮喘患者，并验证如下假说：奥马珠单抗可降低持续性过敏性哮喘患者接受免疫治疗时的全身不良反应发生率。